Vetter dual-chamber system – typical project steps
Approximately a third of protein based therapeutic drugs cannot be kept stable in solution for long periods and require lyophilization. An alternative to the two vial kit system is the Vetter dual-chamber system which offers the advantages of fewer steps of a prefilled syringe making it quicker and easier to administer the drug with less waste of drug product.
Join Vetter for a live Webinar to learn more about the Vetter dual-chamber system and the steps involved from packaging material selection to the design of an optimal lyophilization cycle in a dual chamber system.
The live event will answer the following questions, and more:
• What are the advantages of dual-chamber syringes and cartridges?
• What are the typical project steps in Lifecycle Management when changing from vials to dual-chamber systems?
• Why are packaging material selection, feasibility, and lyophilization cycle development essential in the drug development pathway?
This webinar will be presented live twice at:
- 8AM London/4PM Shanghai
- 3PM London/10AM New York
Please register for the most suitable time.
Presented by
Joerg Zimmermann,
Vice President Development Service
Joerg Zimmermann studied pharmacy in Freiburg, Germany and Cardiff, Wales, and joined Vetter in 1994 as assistant head of production. His first responsibilities were process development and new product introductions with a focus on lyophilization process development. For more than 10 years, Joerg was responsible for the Vetter Site in Langenargen as Director of production, a site with 5 filling lines for aseptically prefilled injection systems. In September 2010, he moved into the role of Director Process Development and Implementation. In 2014, he became Vice President of Vetter Development Service in Germany, covering all aspects of pharmaceutical process development and qualification, development of packaging components, analytical method transfers, and stability studies.
Dr. David Brett,
Team Leader Product and Service Management
Dr. David Brett studied Biological sciences at the University of East Anglia in the UK. He earned an MBA at the University of Bayreuth, Germany, and a PhD in Biochemistry at Imperial College in London. After postdoctoral positions at the Institute of cancer research, he trained at Bioinformatics with a focus on pharmaceutical drug target screening. In the Siemens Healthcare strategy and innovation department, he worked on a number of topics including protein target molecules for cancer & diabetes, e-health, personalized medicine, and molecular imaging. David joined Vetter in 2010 as product and service manager with a focus on innovation in injectable drug-delivery systems, clinical development and commercial manufacturing. He became Team leader of Product and Service Management in 2015, and is responsible for the development of Vetter's service offering to optimally fit customer requirements.
